Integra LifeSciences Holdings Corporation
IART
$22.38
-$1.57-6.56%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 11.49% | -0.41% | 9.68% | -3.14% | -0.25% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 11.49% | -0.41% | 9.68% | -3.14% | -0.25% |
| Cost of Revenue | 12.04% | 6.50% | 18.64% | 5.01% | 5.15% |
| Gross Profit | 11.12% | -5.02% | 4.42% | -7.99% | -3.51% |
| SG&A Expenses | 22.48% | 11.33% | 11.87% | 1.81% | -1.39% |
| Depreciation & Amortization | 22.45% | 17.21% | 22.50% | -2.09% | -14.37% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.92% | 9.33% | 14.66% | 2.63% | 1.29% |
| Operating Income | -15.61% | -55.97% | -18.25% | -33.49% | -6.23% |
| Income Before Tax | -21.89% | -209.42% | -497.10% | -117.56% | -55.06% |
| Income Tax Expenses | -65.58% | -988.63% | -673.06% | -135.10% | -19.87% |
| Earnings from Continuing Operations | -2.01% | -154.85% | -396.41% | -113.54% | -62.54% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.01% | -154.85% | -396.41% | -113.54% | -62.54% |
| EBIT | -15.61% | -55.97% | -18.25% | -33.49% | -6.23% |
| EBITDA | 1.69% | -46.49% | 2.85% | -22.78% | -3.23% |
| EPS Basic | -0.04% | -157.17% | -409.86% | -114.26% | -59.85% |
| Normalized Basic EPS | -25.37% | -71.13% | -24.23% | -37.80% | -3.45% |
| EPS Diluted | 0.40% | -158.33% | -420.40% | -114.55% | -60.05% |
| Normalized Diluted EPS | -25.37% | -71.08% | -24.05% | -37.46% | -3.45% |
| Average Basic Shares Outstanding | -1.98% | -4.07% | -4.39% | -5.05% | -6.71% |
| Average Diluted Shares Outstanding | -1.98% | -4.21% | -4.61% | -5.57% | -6.71% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
